Securities litigation brought against US firm Scios, and its chief executive Richard Casey, has been dismissed by the US District Court for the Northern District of California. The dismissal was with prejuidice, meaning the plaintiffs will have no opportunity to correct their complaint and refile it.
The action, brought by shareholders, alleged violation of the Federal securities laws based on company statements about clinical studies conducted by the University of Colorado regarding Auriculin (anaritide).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze